Vertex Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Revenue	11,971	11,020	9,869	8,931	7,573
Other Revenue	30.7	-	-	-	1
Revenue	12,001	11,020	9,869	8,931	7,574
Revenue Growth (YoY)	8.90%	11.66%	10.51%	17.91%	22.06%
Cost of Revenue	5,561	5,161	4,425	3,608	2,842
Gross Profit	6,441	5,859	5,444	5,323	4,732
Selling, General & Admin	1,753	1,464	1,137	944.7	840.1
Operating Expenses	1,753	1,464	1,137	944.7	840.1
Operating Income	4,687	4,395	4,308	4,378	3,892
Interest Expense	-13.3	-30.6	-44.1	-54.8	-61.5
Interest & Investment Income	490.9	598.1	614.7	144.6	4.9
Currency Exchange Gain (Loss)	-13.7	-27.3	-24.6	-15.1	-13.9
Other Non Operating Income (Expenses)	17.3	-49.3	9.3	-0.6	1.7
EBT Excluding Unusual Items	5,169	4,886	4,863	4,453	3,824
Gain (Loss) on Sale of Investments	-11.3	-9.5	-7.5	-149.1	17.1
Asset Writedown	-379	-	-	-13	-
Other Unusual Items	-2.1	0.5	51.6	57.5	3.1
Pretax Income	4,643	248.5	4,380	4,232	2,730
Income Tax Expense	690	784.1	760.2	910.4	388.3
Earnings From Continuing Operations	3,953	-535.6	3,620	3,322	2,342
Net Income	3,953	-535.6	3,620	3,322	2,342
Net Income to Common	3,953	-535.6	3,620	3,322	2,342
Net Income Growth	-	-	8.96%	41.84%	-13.63%
Shares Outstanding (Basic)	256	258	258	256	258
Shares Outstanding (Diluted)	258	258	261	259	260
Shares Change (YoY)	0.04%	-1.00%	0.54%	-0.31%	-1.33%
EPS (Basic)	15.46	-2.08	14.05	12.97	9.09
EPS (Diluted)	15.32	-2.08	13.89	12.82	9.01
EPS Growth	-	-	8.35%	42.29%	-12.44%
Free Cash Flow	3,194	-790.3	3,337	3,925	2,409
Free Cash Flow Per Share	12.38	-3.06	12.81	15.15	9.27
Gross Margin	53.66%	53.17%	55.16%	59.60%	62.48%
Operating Margin	39.06%	39.88%	43.65%	49.03%	51.39%
Profit Margin	32.94%	-4.86%	36.68%	37.20%	30.92%
Free Cash Flow Margin	26.61%	-7.17%	33.81%	43.95%	31.80%
EBITDA	4,866	4,577	4,477	4,527	4,018
EBITDA Margin	40.55%	41.53%	45.36%	50.69%	53.05%
D&A For EBITDA	178.6	182	169.5	148.3	125.6
EBIT	4,687	4,395	4,308	4,378	3,892
EBIT Margin	39.06%	39.88%	43.65%	49.03%	51.39%
Effective Tax Rate	14.86%	315.53%	17.36%	21.51%	14.22%
Revenue as Reported	12,001	11,020	9,869	-	7,574

Source: S&P Global Market Intelligence. Standard template. Financial Sources.